Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Maintenance treatment with gilteritinib suppresses post-transplant relapse in relapsed/refractory FLT3-mutated acute myeloid leukemia: A Japanese nationwide registry study

View Full Paper
Ask AI
Bookmark
Share

Authors

TITakashi IshidaHUHiroki UchidaATAkiyoshi Takami

Discussion

Loading...

Member takes

Overview

Observational analysis shows improved relapse incidence in FLT3-mutated AML patients following gilteritinib maintenance, highlighting its potential benefits post-HSCT.

Key Points

  • Post-transplant gilteritinib maintenance significantly reduces relapse incidence in acute myeloid leukemia.
  • Among 120 patients, those receiving gilteritinib showed improved outcomes, with relapse rates at 27.6% vs. 44.8%.
  • Analysis from a nationwide registry assessed R/R FLT3-mutated AML and outcomes of gilteritinib maintenance therapy post-HSCT.
  • Findings suggest that gilteritinib maintenance may benefit those undergoing grafts, enhancing overall survival in this population.

Cite This Study

Ishida et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e22chttps://doi.org/10.1182/blood-2025-4289
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Gilteritinib maintenance therapy after allogeneic hematopoietic stem cell transplantation in FLT3-mutated AML: A systematic review and meta-analysis2025
  2. 2Effect of FLT3 maintenance in older FLT3-ITD+ adults undergoing allogeneic HCT. a post hoc analysis of BMT CTN 15062025 · 1 citations
  3. 3A Phase 2 study of sequential administration of gilteritinib after MEC chemotherapy in Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia in adults: Japan adult leukemia study group (JALSG) RR-FLT3-AML220 study2025
  4. 4Real-world effectiveness of gilteritinib beyond second-line therapy in relapsed/refractory FLT3-mutated acute myeloid leukemia: A european multicenter study of 171 patients2025 · 1 citations
  5. 5Gilteritinib in FLT3‐mutated acute myeloid leukemia: A real‐world Italian experience2025 · 6 citations